Details for New Drug Application (NDA): 207093
✉ Email this page to a colleague
NDA 207093 describes FELBAMATE, which is a drug marketed by Amneal Pharms, Novitium Pharma, Taro, Alvogen, Ani Pharms, and Zydus Lifesciences, and is included in eight NDAs. It is available from nine suppliers. Additional details are available on the FELBAMATE profile page.
The generic ingredient in FELBAMATE is felbamate. There are twelve drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the felbamate profile page.
The generic ingredient in FELBAMATE is felbamate. There are twelve drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the felbamate profile page.
Pharmacology for NDA: 207093
| Physiological Effect | Decreased Central Nervous System Disorganized Electrical Activity |
Suppliers and Packaging for NDA: 207093
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| FELBAMATE | felbamate | TABLET;ORAL | 207093 | ANDA | Taro Pharmaceuticals U.S.A., inc. | 51672-4185 | 51672-4185-1 | 100 TABLET in 1 BOTTLE (51672-4185-1) |
| FELBAMATE | felbamate | TABLET;ORAL | 207093 | ANDA | Taro Pharmaceuticals U.S.A., inc. | 51672-4185 | 51672-4185-5 | 90 TABLET in 1 BOTTLE (51672-4185-5) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 400MG | ||||
| Approval Date: | Apr 20, 2017 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 600MG | ||||
| Approval Date: | Apr 20, 2017 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
